Fundraising FoxAditum Bio — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Vianovatxvianovatx.comSeries A · Sep 2021 · $20M
Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections.
BiotechDigital HealthMedical DevicesOakland, US
Donald Ganem(Executive Officer, Director)Benjamine Liu(Director)Ilan Zipkin(Director)
Board seatJoseph Jimenez· per SEC Form D
Co-investorsPMV
Versanis Bioversanisbio.comSeries A · Aug 2021 · $70M
Co-investorsTCG CrossoverAtlas Venture
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.